Correlation Between Fate Therapeutics and Lexaria Bioscience

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and Lexaria Bioscience at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and Lexaria Bioscience into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fate Therapeutics and Lexaria Bioscience Corp, you can compare the effects of market volatilities on Fate Therapeutics and Lexaria Bioscience and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of Lexaria Bioscience. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and Lexaria Bioscience.

Diversification Opportunities for Fate Therapeutics and Lexaria Bioscience

0.81
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Fate and Lexaria is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and Lexaria Bioscience Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lexaria Bioscience Corp and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with Lexaria Bioscience. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lexaria Bioscience Corp has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and Lexaria Bioscience go up and down completely randomly.

Pair Corralation between Fate Therapeutics and Lexaria Bioscience

Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the Lexaria Bioscience. In addition to that, Fate Therapeutics is 1.52 times more volatile than Lexaria Bioscience Corp. It trades about -0.14 of its total potential returns per unit of risk. Lexaria Bioscience Corp is currently generating about -0.08 per unit of volatility. If you would invest  297.00  in Lexaria Bioscience Corp on September 26, 2024 and sell it today you would lose (74.00) from holding Lexaria Bioscience Corp or give up 24.92% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Fate Therapeutics  vs.  Lexaria Bioscience Corp

 Performance 
       Timeline  
Fate Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Lexaria Bioscience Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lexaria Bioscience Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Fate Therapeutics and Lexaria Bioscience Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fate Therapeutics and Lexaria Bioscience

The main advantage of trading using opposite Fate Therapeutics and Lexaria Bioscience positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, Lexaria Bioscience can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexaria Bioscience will offset losses from the drop in Lexaria Bioscience's long position.
The idea behind Fate Therapeutics and Lexaria Bioscience Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets